

# Atopy and multisensitizations in patients with severe asthma.

Jan Romantowski, Marek Niedożytko

*Department of Allergology, Medical University of Gdansk*

## Introduction

Asthma is a chronic inflammatory airway disease. With prevalence estimated at 8% in European adults asthma is an important society problem. Fortunately, with modern inhalation drugs it affects mostly quality of life with low risk of death. Still, 6% of patients experience severe asthma. These patients with high symptom intensity and frequent exacerbations present a challenge for allergologists. Their allergic vs. non-allergic profile might be different from standard asthmatic group.

## Material and methods

Twenty patients (age 22– 67) with severe asthma according to GINA were enrolled. They experienced at least 2 exacerbations during past year and had uncontrolled asthma despite high inhaled steroid use. Microarray serum Alex test (allergen-specific IgE to 295 extracts and components) has been performed together with Complete Blood count. Total IgE concentration detection threshold was 20 U/ml.

## Results

The most prevalent allergen was grass pollen (30%). Food sensitizations were discovered in 25% of patients. Interestingly, in 5 out of 20 patients sensitization to insect venom was observed, with only one reporting allergy. In total, 12 (60%) patients had allergic asthma. Microarrays were able to detect additional inhaled allergen sensitization in 8 (40%) patients. The most prevalent new detection were grass pollen and fungi. Fifty-five percent of patients had increased blood eosinophilia (over 0.35 G/l). According to Polish guidelines, 30% of patients would not qualify for biological treatment (lack of perennial allergen, low eosinophilia)

## Conclusions

Allergen microarrays is a useful tool in thorough diagnosis of inhaled allergen sensitizations in patients with severe asthma. High presence of insect venom sensitizations might show danger of post-stinging anaphylaxis in severe asthma. Also, the results point out a need for new biologicals development, since high number of patients cannot receive currently available therapies.